Fen Phen and PPH, Dietary Supplements, Primary Pulmonary Hypertension
Fen Phen is a combination drug that was introduced as an anti-obesity or weight suppressant treatment in the 1990's. Fen Phen was recalled from the market by the FDA in 1997 because of data showing that this drug caused heart valve damage and primary pulmonary hypertension. Studies showed that patients who took these appetite suppressants, particularly those whose treatment lasted for more than 3 months, were much more likely to develop primary pulmonary hypertension. The risk of getting PPH increased by 28 times compared to those who had not been treated with Fen Phen.
Fenfluramine, also known as pondimin, was combined with phentermine to create the combination of Fen Phen. (A different formulation of fenfluramine, called dexfenfluramine, was marketed under the name of Redux. This drug was also combined with phentermine to create the combination of Fen Phen.) Although both drugs, fenfluramine and phentermine, had been sold individually for many years, the combination drug was introduced by Home Health Products in the 1990s. (Home Health Products later changed its name to Wyeth Pharmaceuticals.) When the FDA recall occurred, fenfluramine and dexfenfluramine were removed from the market. The detrimental side effects of Fen Phen, including heart valve defects and primary pulmonary hypertension, are attributed to the drugs Pondimin (fenfluramine) and Redux (dexfenfluramine). Phentermine is still sold as an anti-obesity and diet suppressant drug.
How Fen Phen Worked
Fenfluramine was designed to increase the level of neurotransmitter serotonin in the blood. Increased levels of serotonin depress central nervous system activity, which regulates mood and appetite. The end result was a feeling of fullness and loss of appetite. Phentermine also worked on the neurotransmitters in the brain, but instead of being a depressant like fenfluramine, it was a stimulant. It stimulated the "fight or flight" response in the body, which causes the heart rate and blood pressure to increase. This stimulation also reduces or dampens the hunger signal. Phentermine continues to be sold commercially and is similar to other appetite suppressants, such as sibutramine or dextroamphetamine.
It is thought that fenfluramine and dexfenfluramine cause narrowing of the pulmonary arteries and this narrowing is what leads to primary pulmonary hypertension.
Diagnosis of PPH Due to Fen Phen
Although Redux and Pondimin has been removed from the market since 1997, patients are still being diagnosed with primary pulmonary hypertension due to treatment with these drugs. It can take as long as 10 years for the symptoms and effects of PPH to appear after first exposure to Redux or Pondimin treatment. Patients who took these drugs over a longer time period are more likely to develop PPH than those who took the drugs for less than 3 months.
Diagnosis of PPH
If you are being evaluated for PPH symptoms or have been diagnosed with PPH, it is best to inform your physician of any previous use of either Redux or Pondimin. In addition, you should contact an experienced PPH personal injury attorney to find out if compensation might be available. The lawyer will thoroughly discuss your case to determine if a lawsuit should be initiated to hold the manufacturers and/or distributors of the diet pill that caused your illness financially liable. The lawyer might also help you if you have suffered other adverse events since your PPH diagnosis, such as car accidents, disability, unemployment and divorce. In fact, some personal injury lawyers are part of law firms that include highly experienced auto accident attorneys, DWI attorneys and divorce law specialists.
Last Revision: January 26, 2011
MediaFact is a major online source of information about drug side effects connected with Stevens Johnson Syndrome and Primary Pulmonary Hypertension.
